All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Biomarkers and therapeutic targets in giant cell tumor of bone: A comprehensive review

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F25%3A00082472" target="_blank" >RIV/00159816:_____/25:00082472 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216224:14310/25:00141796

  • Result on the web

    <a href="https://www.sciencedirect.com/science/article/pii/S8756328225001784?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S8756328225001784?via%3Dihub</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.bone.2025.117566" target="_blank" >10.1016/j.bone.2025.117566</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Biomarkers and therapeutic targets in giant cell tumor of bone: A comprehensive review

  • Original language description

    Giant cell tumor of bone (GCTB) is an intermediate locally aggressive osteolytic tumor with low metastatic potential and a high recurrence rate. It comprises two main types of cells-neoplastic mononuclear stromal cells and osteoclast-like giant cells-which are responsible for the resorption of bone. In addition to surgery, which is the primary treatment of choice, adjuvant therapy is used to lower the risk of recurrence. However, denosumab, the standard adjuvant treatment currently used, only targets osteoclast-like giant cells and does not affect neoplastic stromal cells. Since some GCTBs are inoperable, or even after surgery, there can be residual tumor cells at the site of the tumor, novel therapies, especially those that target neoplastic stromal cells, are needed. Both cell types in GCTB show altered expression of various specific genes and molecules, and these deregulated molecular profiles could serve as biomarkers and targets for targeted therapy. Herein, we summarize the potential biomarkers for both cell types in GCTB and therapeutic agents targeting these molecules with the hope of finding a therapy with improved outcomes and a lower risk of recurrence.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30211 - Orthopaedics

Result continuities

  • Project

    Result was created during the realization of more than one project. More information in the Projects tab.

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2025

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Bone

  • ISSN

    8756-3282

  • e-ISSN

    1873-2763

  • Volume of the periodical

    199

  • Issue of the periodical within the volume

    Oct 2025

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    14

  • Pages from-to

    117566

  • UT code for WoS article

    001517069900001

  • EID of the result in the Scopus database